CoChat

High-Resolution Serum Proteomic Profiling of Alzheimer Disease Samples Reveals Disease-Specific, Carrier-Protein–Bound Mass Signatures

Lopez, Mary F, Mikulskis, Alvydas, Kuzdzal, Scott, Bennett, David A, Kelly, Jeremiah, Golenko, Eva, DiCesare, Joseph, Denoyer, Eric, Patton, Wayne F, Ediger, Richard, Sapp, Lisa, Ziegert, Tillmann, Lynch, Christopher, Kramer, Susan, Whiteley, Gordon R, Wall, Michael R, Mannion, David P, della Cioppa, Guy, Rakitan, John S, Wolfe, Gershon M · 2005 · Clinical Chemistry
Cited by 137

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Background: Researchers typically search for disease markers using a “targeted” approach in which a hypothesis about the disease mechanism is tested and experimental results either confirm or disprove the involvement of a particular gene or protein in the disease. Recently, there has been interest in developing disease diagnostics based on unbiased quantification of differences in global patterns of protein and peptide masses, typically in blood from individuals with and without disease. We combined a suite of methods and technologies, including novel sample preparation based on carrier-protein capture and biomarker enrichment, high-resolution mass spectrometry, a unique cohort of well-characterized persons with and without Alzheimer disease (AD), and powerful bioinformatic analysis, that add statistical and procedural robustness to biomarker discovery from blood. Methods: Carrier-protein–bound peptides were isolated from serum samples by affinity chromatography, and peptide mass spectra were acquired by a matrix-assisted laser desorption/ionization (MALDI) orthogonal time-of-flight (O-TOF) mass spectrometer capable of collecting data over a broad mass range (100 to >300 000 Da) in a single acquisition. Discriminatory analysis of mass spectra was used to process and analyze the raw mass spectral data. Results: Coupled with the biomarker enrichment protocol, the high-resolution MALDI O-TOF mass spectra provided informative, reproducible peptide signatures. The raw mass spectra were analyzed and used to build discriminant disease models that were challenged with blinded samples for classification. Conclusions: Carrier-protein enrichment of disease biomarkers coupled with high-resolution mass spectrometry and discriminant pattern analysis is a powerful technology for diagnostics and population screening. The mass fingerprint model successfully classified blinded AD patient and control samples with high sensitivity and specificity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1373/clinchem.2005.053090

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 137

Metadata

Authors
Lopez, M. F., Mikulskis, A., Kuzdzal, S., Bennett, D. A., Kelly, J., Golenko, E., DiCesare, J., Denoyer, E., Patton, W. F., Ediger, R., Sapp, L., Ziegert, T., Lynch, C., Kramer, S., Whiteley, G. R., Wall, M. R., Mannion, D. P., della Cioppa, G., Rakitan, J. S., & Wolfe, G. M.
Venue
Clinical Chemistry
Published
2005-10-01
Volume
51
Issue
10
Pages
1946-1954
ISSN
  • 0009-9147 (ISSN-L)
  • 1530-8561
OpenAlex
W2104585835
Cited by
137
References
3
FWCI
7.08
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: High-Resolution Serum Proteomic Profiling of Alzheimer Disease Samples Reveals Disease-Specific, Carrier-Protein–Bound Mass Signatures. https://app.cochat.ai/papers/10.1373/clinchem.2005.053090
The paper
Lopez, M. F., Mikulskis, A., Kuzdzal, S., Bennett, D. A., Kelly, J., Golenko, E., DiCesare, J., Denoyer, E., Patton, W. F., Ediger, R., Sapp, L., Ziegert, T., Lynch, C., Kramer, S., Whiteley, G. R., Wall, M. R., Mannion, D. P., della Cioppa, G., Rakitan, J. S., & Wolfe, G. M. (2005). High-Resolution Serum Proteomic Profiling of Alzheimer Disease Samples Reveals Disease-Specific, Carrier-Protein–Bound Mass Signatures. Clinical Chemistry. https://doi.org/10.1373/clinchem.2005.053090

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.